November 2, 2016 05:38 PM EDT

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

John Carroll

Editor & Founder

PTC Therapeutics $PTCT hasn’t yet lost the right to market its failed Duchenne muscular dystrophy drug Translarna in Europe. But the biotech’s exec team is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC sees high­er reg­u­la­to­ry risk in fight to keep its Duchenne drug on the Eu­ro­pean mar­ket

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy